Clinical trials: Retinal Vessels
AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP)
Retinal Investigation Using Optos OCT Device
Retinal investigation using OCT with control and diseased eyes
- Conditions
- AMD - Age-Related Macular Degeneration, Retinitis Pigmentosa (RP), Diabetic Retinopathy, Control Patients
- Trial name
- NCT06846151
- Testing
- retinal functional imaging
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Optos, PLC
Diabetes, Diabetic Retinopathy
Diabetic Retinopathy Functional Evaluation Study: Monitoring Carotenoid Vitamins Treatment Using ERG
To evaluate the differences in retinal function as measured by ERG in diabetics with and without retinopathy 2) the ability of the Chromatic Electroretinogram (chERG) to detect changes in global retinal function following…
- Trial name
- NCT04117022
- Testing
- DVS supplementation
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- ZeaVision, LLC
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Diabetic Retinopathy, Diabetic Eye Problems
Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
The duration of diabetes is directly related to eye complications. Diabetic retinopathy affects 80 percent of those who have had diabetes for 20 years or more.
- Conditions
- Diabetic Retinopathy, Diabetic Eye Problems, Diabetic Macular Edema
- Trial name
- NCT04805541
- Testing
- Color Fundus Photography, Mydriatic Agent, EyeCheckup - AI Based DR Screening
- Where
- Turkey (Türkiye)
- Volunteers
- 900 people
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Neovascular Age-Related Macular Degeneration
Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular Degeneration
Neovascular age-related macular degeneration is characterized by the presence of choroidal neovascularization (CNV), which consists of abnormal blood vessels originating from the choroid that can lead to hemorrhage, fluid…
- Trial name
- SWIFT (NCT04264819)
- Testing
- RTH258/Brolucizumab
- Where
- 51 sites in France
- Volunteers
- 295 people
- Sponsor
- Novartis Pharmaceuticals
Non-proliferative Diabetic Retinopathy
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Non-proliferative Diabetic Retinopathy (NPDR)
This Phase 3 Study will evaluate the efficacy and safety of KSI-301 in participants with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
- Trial name
- GLOW (NCT05066230)
- Testing
- KSI-301
- Where
- 61 sites in United States, Czechia and 5 more
- Volunteers
- 253 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Retinopathy
Study of Topical Ocular PAN-90806 in PDR
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with proliferative diabetic retinopathy.
- Trial name
- NCT02475109
- Testing
- PAN-90806 Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- PanOptica, Inc.
Age Related Macular Degeneration
A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）
A randomized, double-blind, parallel controlled, multicenter clinical trial to compare the efficacy and safety of LY09004 and EYLEA in the Treatment of Wet Age-related Macular Degeneration（wAMD)
- Trial name
- NCT04572698
- Testing
- LY09004, Eylea
- Volunteers
- 416 people
- Sponsor
- Luye Pharma Group Ltd.
Diabetic Retinopathy
OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy
The purpose of this study is to determine whether supplementation with OcuStem, a nutritional supplement, will reduce the progression of mild to moderate diabetic retinopathy.
- Trial name
- NCT02353923
- Testing
- OcuStem Supplementation
- Volunteers
- 30 people
- Sponsor
- Aidan Products LLC
Cerebral Amyloid Angiopathy
A Study of AMDX-2011P in Participants With CAA
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with cerebral amyloid angiopathy (CAA).
- Trial name
- NCT05709314
- Testing
- AMDX-2011P
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Amydis Inc.
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
A Study Assessing AR-13503 Implant in Subjects With nAMD or DME
First-in-Human Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME)
- Trial name
- NCT03835884
- Testing
- AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose
- Where
- 6 sites in United States
- Volunteers
- 18 people
- Sponsor
- Aerie Pharmaceuticals